Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free NMTC Stock Alerts

NeuroOne Medical Technologies (NMTC) Financials

NeuroOne Medical Technologies logo
$1.77 -0.21 (-10.61%)
As of 08/28/2026 04:00 PM Eastern
Compare
Annual Income Statements for NeuroOne Medical Technologies

Annual Income Statements for NeuroOne Medical Technologies

This table shows NeuroOne Medical Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.04 -0.06 -0.05 -5.06 -6.78 -12 -9.95 -10.00 -12 -12 -3.61
Consolidated Net Income / (Loss)		 -0.04 -0.06 -0.05 -5.06 -6.78 -14 -9.95 -10.00 -12 -12 -3.61
Net Income / (Loss) Continuing Operations		 -0.04 -0.03 -0.03 -5.06 -6.78 -12 -9.95 -10.00 -12 -12 -3.61
Total Pre-Tax Income 		-0.04 -0.03 -0.03 -4.71 -6.78 -2.02 -9.95 -10.00 -12 -12 -3.61
Total Operating Income		 -0.04 -0.03 -0.03 -3.07 -5.81 -4.90 -10 -10 -12 -12 -4.23
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 -0.10 -0.07 0.46 1.08 5.14
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.24 2.12 3.41 3.45 12
Operating Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.24 2.12 3.41 3.45 12
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.24 1.50 2.37 3.96
Operating Cost of Revenue		 - - - - - 0.00 0.28 0.24 1.50 2.37 3.96
Total Operating Expenses		 0.04 0.03 0.03 3.07 5.81 4.90 10 12 14 13 12
Selling, General & Admin Expense		 0.04 0.03 0.03 2.34 4.28 4.75 6.26 6.98 6.93 7.90 7.38
Research & Development Expense		 - - - 0.74 1.53 2.08 3.93 4.93 6.94 5.07 4.98
Total Other Income / (Expense), net		 -0.00 0.00 0.00 -1.64 -0.97 -6.72 0.27 0.03 0.10 -0.43 0.62
Interest Expense		 - - - 1.40 0.84 7.52 0.00 - 0.00 0.23 0.33
Other Income / (Expense), net		 -0.00 - - -0.24 -0.13 0.80 0.27 0.03 0.10 -0.20 0.96
Income Tax Expense		 0.00 0.00 0.00 - - 0.00 - 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.01) ($0.01) ($0.01) ($0.77) ($0.57) ($2.52) ($0.93) ($0.63) ($0.65) ($0.46) ($0.09)
Weighted Average Basic Shares Outstanding		 5.07M 5.07M 5.07M 6.61M 11.86M 5.42M 10.70M 16.00M 18.12M 26.76M 40.15M
Diluted Earnings per Share		 ($0.01) ($0.01) ($0.01) ($0.77) ($0.57) ($2.52) - - ($0.65) ($0.46) ($0.09)
Weighted Average Diluted Shares Outstanding		 5.07M 5.07M 5.07M 6.61M 11.86M 5.42M 10.70M 16.24M 18.12M 26.76M 40.15M

Quarterly Income Statements for NeuroOne Medical Technologies

This table shows NeuroOne Medical Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.34 -2.86 -2.77 -3.35 1.79 -2.27 -1.50 -1.62 -1.44 -2.38 -2.01
Consolidated Net Income / (Loss)		 -3.34 -2.86 -2.77 -3.35 1.79 -2.27 -1.50 -1.62 -1.44 -2.38 -2.01
Net Income / (Loss) Continuing Operations		 -3.34 -2.86 -2.77 -3.35 1.79 -2.27 -1.50 -1.62 -1.44 -2.38 -2.01
Total Pre-Tax Income 		-3.34 -2.86 -2.77 -3.35 1.79 -2.27 -1.50 -1.62 -1.44 -2.38 -2.01
Total Operating Income		 -3.39 -2.89 -2.79 -2.82 1.71 -2.68 -1.89 -1.37 -1.71 -2.40 -2.42
Total Gross Profit		 0.27 0.39 0.28 0.14 1.93 0.77 0.91 1.53 1.57 0.99 1.18
Total Revenue		 0.98 1.38 0.83 0.27 6.27 1.39 1.70 2.74 2.89 1.86 1.97
Operating Revenue		 0.98 1.38 0.83 0.27 6.27 1.39 1.70 2.74 2.89 1.86 1.97
Total Cost of Revenue		 0.71 0.99 0.54 0.13 1.35 0.62 0.78 1.21 1.32 0.87 0.79
Operating Cost of Revenue		 0.71 0.99 0.54 0.13 1.35 0.62 0.78 1.21 1.32 0.87 0.79
Total Operating Expenses		 3.66 3.28 3.08 2.96 3.22 3.45 2.80 2.90 3.28 3.39 3.61
Selling, General & Admin Expense		 2.17 2.00 1.88 1.84 2.04 1.94 1.62 1.78 1.89 1.92 2.18
Research & Development Expense		 1.48 1.27 1.19 1.11 1.17 1.51 1.18 1.12 1.39 1.47 1.43
Total Other Income / (Expense), net		 0.05 0.03 0.03 -0.53 0.07 0.41 0.39 -0.25 0.27 0.02 0.42
Interest Expense		 0.00 0.00 0.00 0.23 0.32 0.00 0.01 - 0.00 0.00 0.00
Other Income / (Expense), net		 0.05 0.03 0.03 -0.30 0.40 0.41 0.40 0.08 0.27 0.02 0.42
Income Tax Expense		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Basic Earnings per Share		 ($0.14) ($0.11) ($0.10) ($0.11) $0.06 ($0.44) ($0.19) ($0.05) ($0.03) ($0.28) ($0.23)
Weighted Average Basic Shares Outstanding		 24.00M 25.91M 27.35M 26.76M 30.84M 5.19M 8.10M 40.15M 50.33M 8.48M 8.66M
Diluted Earnings per Share		 ($0.14) ($0.11) ($0.10) ($0.11) $0.06 ($0.44) ($0.19) ($0.05) ($0.03) ($0.28) ($0.28)
Weighted Average Diluted Shares Outstanding		 24.00M 25.91M 27.35M 26.76M 30.88M 5.19M 8.10M 40.15M 50.33M 8.48M 8.74M
Weighted Average Basic & Diluted Shares Outstanding		 25.93M 27.52M 30.81M 0.00 - - - 0.00 - - 9.11M

Annual Cash Flow Statements for NeuroOne Medical Technologies

This table details how cash moves in and out of NeuroOne Medical Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents		 -0.00 -0.00 0.00 -0.50 0.25 -3.75 2.86 1.26 -2.84 -3.86 5.11
Net Cash From Operating Activities		 -0.03 -0.03 -0.02 -2.11 -5.40 -3.43 -8.60 -7.52 -13 -11 -2.84
Net Cash From Continuing Operating Activities		 -0.03 -0.03 -0.02 -2.11 -5.40 -11 -8.60 -7.52 -13 -11 -2.84
Net Income / (Loss) Continuing Operations		 -0.04 -0.05 -0.03 -5.06 -6.78 -14 -9.95 -10.00 -12 -12 -3.61
Consolidated Net Income / (Loss)		 -0.04 -0.06 -0.05 -5.06 -6.78 -14 -9.95 -10.00 -12 -12 -3.61
Depreciation Expense		 - - - - 0.03 0.05 0.08 0.12 0.20 0.25 0.26
Amortization Expense		 - - - 1.26 0.23 - 0.00 -0.01 -0.05 0.10 0.19
Non-Cash Adjustments To Reconcile Net Income		 0.00 0.02 -0.00 0.79 1.23 3.07 1.78 1.16 1.25 1.91 0.74
Changes in Operating Assets and Liabilities, net		 0.01 -0.00 0.01 0.90 -0.10 -0.43 -0.51 1.21 -2.43 -0.95 -0.43
Net Cash From Investing Activities		 0.00 0.00 0.00 -0.09 -0.12 -0.12 -0.07 -3.24 2.65 -0.12 -0.08
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 -0.09 -0.12 -0.12 -0.07 -3.24 2.65 -0.12 -0.08
Purchase of Property, Plant & Equipment		 - - - - -0.06 -0.12 -0.07 -0.28 -0.38 -0.12 -0.08
Net Cash From Financing Activities		 0.03 0.03 0.02 1.70 5.77 7.32 12 12 7.40 7.27 8.03
Net Cash From Continuing Financing Activities		 0.03 0.03 0.02 1.70 5.77 7.32 12 12 7.40 7.27 8.03
Repayment of Debt		 - 0.00 0.00 -0.10 -0.28 - -0.00 - 0.00 -0.08 -0.30
Issuance of Common Equity		 - - - 0.00 6.27 0.39 11 13 7.52 7.43 8.38
Other Financing Activities, net		 - - - 0.02 -0.22 -1.42 0.24 -1.33 -0.12 -0.08 -0.05

Quarterly Cash Flow Statements for NeuroOne Medical Technologies

This table details how cash moves in and out of NeuroOne Medical Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -2.64 -0.25 -0.81 -0.16 -0.33 0.19 6.72 -1.47 -3.01 -0.76 -0.76
Net Cash From Operating Activities		 -3.81 -2.18 -2.36 -2.67 0.21 -0.06 -1.46 -1.53 -3.12 -1.33 -1.08
Net Cash From Continuing Operating Activities		 -3.81 -2.18 -2.36 -2.67 0.21 -0.06 -1.46 -1.53 -3.12 -1.33 -1.08
Net Income / (Loss) Continuing Operations		 -3.34 -2.86 -2.77 -3.35 1.79 -2.27 -1.50 -1.62 -1.44 -2.38 -2.01
Consolidated Net Income / (Loss)		 -3.34 -2.86 -2.77 -3.35 1.79 -2.27 -1.50 -1.62 -1.44 -2.38 -2.01
Depreciation Expense		 0.06 0.06 0.06 0.06 0.07 0.07 0.07 0.06 0.07 0.06 0.05
Non-Cash Adjustments To Reconcile Net Income		 0.34 0.39 0.37 0.82 0.11 -0.11 0.04 0.70 0.17 0.38 -0.02
Changes in Operating Assets and Liabilities, net		 -0.86 0.23 -0.02 -0.30 -1.94 2.26 -0.07 -0.68 -1.91 0.61 0.90
Net Cash From Investing Activities		 -0.04 -0.03 -0.01 -0.04 -0.02 -0.00 -0.04 -0.01 -0.04 -0.04 -0.02
Net Cash From Continuing Investing Activities		 -0.04 -0.03 -0.01 -0.04 -0.02 -0.00 -0.04 -0.01 -0.04 -0.04 -0.02
Purchase of Property, Plant & Equipment		 -0.04 - - -0.04 -0.02 -0.00 - -0.01 -0.04 -0.04 -0.02
Net Cash From Financing Activities		 1.21 1.96 1.56 2.54 -0.51 0.25 8.23 0.07 0.15 0.61 0.35
Net Cash From Continuing Financing Activities		 1.21 1.96 1.56 2.54 -0.51 0.25 8.23 0.07 0.15 0.61 0.35
Repayment of Debt		 0.00 -0.16 -0.08 0.16 -0.29 -0.27 -0.97 1.23 0.00 - -0.01
Issuance of Common Equity		 1.22 2.13 1.68 2.39 -0.21 0.62 9.20 -1.23 -0.02 0.69 0.36
Other Financing Activities, net		 -0.01 -0.01 -0.05 -0.01 -0.01 -0.11 -0.00 0.07 0.17 -0.06 -0.00

Annual Balance Sheets for NeuroOne Medical Technologies

This table presents NeuroOne Medical Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 0.00 0.76 0.25 0.22 0.53 4.76 7.94 13 8.10 5.37 11
Total Current Assets		 0.00 0.58 0.03 0.02 0.30 4.16 7.29 12 7.31 4.63 10
Cash & Equivalents		 0.00 0.52 0.03 0.01 0.26 4.04 6.90 8.16 5.32 1.46 6.57
Accounts Receivable		 - - - - - - 0.05 0.03 0.00 0.18 1.26
Inventories, net		 - - - - - 0.00 0.10 0.70 1.73 2.64 2.23
Prepaid Expenses		 - 0.05 0.01 0.01 0.04 0.12 0.24 0.30 0.26 0.22 0.14
Other Current Assets		 - - - - - - - - - 0.14 0.02
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.05 0.17 0.22 0.35 0.53 0.42 0.26
Total Noncurrent Assets		 0.00 0.18 0.22 0.20 0.18 0.44 0.42 0.29 0.26 0.32 0.30
Intangible Assets		 - 0.18 0.22 0.20 0.18 0.16 0.13 0.11 0.09 0.07 0.04
Other Noncurrent Operating Assets		 0.00 - - - 0.00 0.28 0.29 0.18 0.17 0.25 0.26
Total Liabilities & Shareholders' Equity		 0.00 0.76 0.25 0.22 0.53 4.76 7.94 13 8.10 5.37 11
Total Liabilities		 0.08 1.02 5.29 4.61 1.77 2.69 1.38 3.22 1.85 4.55 3.71
Total Current Liabilities		 0.08 0.68 3.91 3.80 1.77 2.36 1.18 3.10 1.79 2.21 2.30
Accounts Payable		 0.06 - 0.00 0.22 1.15 0.76 0.53 0.93 0.69 1.03 1.01
Accrued Expenses		 - 0.49 1.02 1.59 0.62 0.51 0.64 0.72 1.11 1.18 1.29
Total Noncurrent Liabilities		 0.00 0.35 1.38 0.82 0.00 0.34 0.20 0.12 0.06 2.33 1.41
Other Noncurrent Operating Liabilities		 - 0.35 1.38 0.82 0.00 0.34 0.20 0.12 0.00 2.33 1.41
Total Equity & Noncontrolling Interests		 -0.08 -0.27 -5.04 -4.40 -1.24 2.07 6.55 9.60 6.25 0.82 7.07
Total Preferred & Common Equity		 -0.08 -0.27 -5.04 -4.40 -1.24 2.07 6.55 9.60 6.25 0.82 7.07
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.08 -0.27 -5.04 -4.40 -1.24 2.07 6.55 9.60 6.25 0.82 7.07
Common Stock		 0.05 0.00 0.29 6.06 16 33 47 60 69 76 86
Retained Earnings		 -0.18 -0.27 -5.32 -10 -17 -31 -41 -51 -63 -75 -79
Other Equity Adjustments		 0.05 - - - - - - - - - 0.00

Quarterly Balance Sheets for NeuroOne Medical Technologies

This table presents NeuroOne Medical Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Assets		 5.82 5.39 4.91 6.49 4.46 11 8.58 7.57 6.19
Total Current Assets		 5.09 4.71 4.09 5.71 3.75 10 8.07 7.11 5.79
Cash & Equivalents		 2.68 2.43 1.62 1.13 1.32 8.04 3.56 2.80 2.05
Accounts Receivable		 0.54 0.56 0.41 2.37 0.32 0.00 2.66 1.90 1.10
Inventories, net		 1.61 1.31 1.79 1.93 1.83 1.90 1.67 2.10 2.29
Prepaid Expenses		 0.26 0.41 0.26 0.19 0.21 0.23 0.15 0.28 0.32
Other Current Assets		 - - - 0.08 0.07 - 0.02 - 0.03
Plant, Property, & Equipment, net		 0.51 0.50 0.47 0.38 0.33 0.31 0.24 0.23 0.20
Total Noncurrent Assets		 0.22 0.19 0.35 0.40 0.37 0.33 0.27 0.25 0.19
Intangible Assets		 0.08 0.08 0.07 0.06 0.06 0.05 0.04 0.03 0.03
Other Noncurrent Operating Assets		 0.14 0.11 0.28 0.34 0.31 0.28 0.23 0.22 0.17
Total Liabilities & Shareholders' Equity		 5.82 5.39 4.91 6.49 4.46 11 8.58 7.57 6.19
Total Liabilities		 1.40 1.54 1.90 3.56 3.33 2.64 2.18 2.49 2.42
Total Current Liabilities		 1.38 1.54 1.69 1.57 1.76 1.43 1.26 1.69 2.04
Accounts Payable		 0.76 0.78 0.76 0.74 0.91 0.47 0.55 0.93 0.91
Accrued Expenses		 0.62 0.76 0.93 0.83 0.85 0.96 0.71 0.76 1.14
Total Noncurrent Liabilities		 0.02 0.00 0.21 1.99 1.57 1.22 0.92 0.80 0.38
Capital Lease Obligations		 - 0.00 0.21 - - 0.18 - 0.09 0.07
Other Noncurrent Operating Liabilities		 0.02 - - 1.99 1.57 1.04 0.92 0.71 0.30
Total Equity & Noncontrolling Interests		 4.42 3.85 3.01 2.94 1.13 8.18 6.40 5.08 3.77
Total Preferred & Common Equity		 4.42 3.85 3.01 2.94 1.13 8.18 6.40 5.08 3.77
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4.42 3.85 3.01 2.94 1.13 8.18 6.40 5.08 3.77
Common Stock		 70 73 75 76 77 85 86 88 88
Retained Earnings		 -66 -69 -72 -73 -75 -77 -80 -82 -84
Other Equity Adjustments		 - - - - - - - - 0.00

Annual Metrics And Ratios for NeuroOne Medical Technologies

This table displays calculated financial ratios and metrics derived from NeuroOne Medical Technologies' official financial filings.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
DEI Shares Outstanding		 5,073,000.00 5,073,000.00 5,073,000.00 7,864,994.00 13,490,204.00 22,052,294.00 12,000,585.00 16,209,232.00 23,919,184.00 25,930,926.00 25,930,926.00
DEI Adjusted Shares Outstanding		 5,073,000.00 5,073,000.00 5,073,000.00 7,864,994.00 13,490,204.00 22,052,294.00 12,000,585.00 16,209,232.00 23,919,184.00 25,930,926.00 25,930,926.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.01 -0.01 -0.01 -0.64 -0.50 -0.53 -0.83 -0.62 -0.50 -0.48 -0.14
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -38.11% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 772.60% 60.73% 1.33% 250.35%
EBITDA Growth		 -18.62% 14.70% -5.49% -6,194.53% 0.00% 28.72% -143.56% -0.28% -18.33% -0.30% 76.01%
EBIT Growth		 -18.62% 14.70% -5.49% -10,057.23% 0.00% 31.05% -142.70% -0.55% -18.60% -1.94% 72.94%
NOPAT Growth		 -43.12% 13.92% -5.49% -9,321.12% 0.00% 15.67% -108.44% 1.83% -19.19% 0.57% 64.45%
Net Income Growth		 -18.62% -73.44% 24.00% -10,488.02% 0.00% -101.15% 27.07% -0.52% -18.60% -3.87% 70.73%
EPS Growth		 0.00% 0.00% 0.00% -7,600.00% 0.00% -342.11% 0.00% 0.00% 0.00% 29.23% 80.43%
Operating Cash Flow Growth		 -4.30% -15.50% 30.18% -9,888.03% 0.00% 36.52% -151.16% 12.59% -71.38% 14.55% 74.23%
Free Cash Flow Firm Growth		 154.10% -53.31% 14,639.96% -137.82% 0.00% 0.00% -95.83% 24.93% -86.69% 38.46% 38.83%
Invested Capital Growth		 -3,638.87% -73.26% -1,097.38% -257.75% 0.00% 35.73% 63.92% -342.37% 163.90% -164.96% 178.70%
Revenue Q/Q Growth		 3.48% -100.00% 100.00% 0.00% 0.00% 0.00% 28.11% 1,261.70% 5.55% -35.79% 25.64%
EBITDA Q/Q Growth		 -26.64% 24.05% -19.99% 10.91% 0.00% -9,143.68% -96.47% 11.41% -16.16% 0.98% 37.99%
EBIT Q/Q Growth		 -26.64% 24.05% -19.99% -43.76% 0.00% 0.00% -95.27% 11.31% -16.38% 0.11% 35.84%
NOPAT Q/Q Growth		 -25.49% 24.05% -19.99% -33.34% 0.00% 0.00% 7.00% 11.03% -17.32% 2.84% 25.49%
Net Income Q/Q Growth		 -23.45% -17.13% 26.46% -47.26% 0.00% 0.00% -26.38% 11.26% -17.44% -1.78% 32.44%
EPS Q/Q Growth		 0.00% 0.00% 50.00% -42.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 40.00%
Operating Cash Flow Q/Q Growth		 -32.68% 8.13% -232.22% -9,888.03% 0.00% 29.24% -36.53% 28.84% -43.73% 2.10% 28.68%
Free Cash Flow Firm Q/Q Growth		 178.58% -74.48% 6,686.62% -203.63% 0.00% 0.00% 9.45% 31.13% -44.57% 28.17% -52.83%
Invested Capital Q/Q Growth		 -300.25% -12.59% -785.03% -36.53% 0.00% 5.88% -155.78% -449.28% 17.23% -139.84% 60.37%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% -40.23% -3.34% 13.40% 31.27% 42.50%
EBITDA Margin		 -4,688.75% 0.00% 0.00% 0.00% 0.00% 0.00% -4,060.11% -466.62% -343.52% -340.02% -23.29%
Operating Margin		 -4,646.05% 0.00% 0.00% 0.00% 0.00% 0.00% -4,205.75% -473.14% -350.84% -344.26% -34.94%
EBIT Margin		 -4,688.75% 0.00% 0.00% 0.00% 0.00% 0.00% -4,093.35% -471.67% -348.03% -350.10% -27.04%
Profit (Net Income) Margin		 -4,688.75% 0.00% 0.00% 0.00% 0.00% 0.00% -4,094.60% -471.67% -348.03% -356.74% -29.80%
Tax Burden Percent		 100.00% 203.34% 146.50% 107.45% 100.00% 675.98% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 142.12% 114.10% 49.24% 100.03% 100.00% 100.00% 101.89% 110.21%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,835.48% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,716.65% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,487.09% 0.00%
Return on Equity (ROE)		 110.37% 107.57% 27.48% 190.78% 240.75% -3,292.36% -230.81% -123.77% -149.61% -348.39% -91.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,108.52% 0.00% -816.25%
Operating Return on Assets (OROA)		 -9,929.86% 0.00% 0.00% 0.00% 0.00% 0.00% -156.64% -96.33% -113.38% -179.53% -40.50%
Return on Assets (ROA)		 -9,929.86% 0.00% 0.00% 0.00% 0.00% 0.00% -156.69% -96.33% -113.38% -182.93% -44.63%
Return on Common Equity (ROCE)		 110.37% 107.57% 27.48% 190.78% 240.75% -3,292.36% -230.81% -123.77% -149.61% -348.39% -91.34%
Return on Equity Simple (ROE_SIMPLE)		 102.42% 77.14% 17.95% 100.43% 547.94% -660.17% -151.79% -104.12% -189.77% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.03 -0.02 -0.02 -2.15 -4.07 -3.43 -7.15 -7.02 -8.37 -8.32 -2.96
NOPAT Margin		 -3,252.24% 0.00% 0.00% 0.00% 0.00% 0.00% -2,944.03% -331.20% -245.59% -240.98% -24.46%
Net Nonoperating Expense Percent (NNEP)		 76.23% 420.29% -11.03% 302.48% -1,040.00% -620.59% -56.30% -33.01% -42.55% -118.83% -16.11%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -132.74% -1,012.28% -41.83%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 113.56% 11.41% 43.90% 68.73% 32.70%
SG&A Expenses to Revenue		 4,746.05% 0.00% 0.00% 0.00% 0.00% 0.00% 2,576.69% 329.21% 203.26% 228.84% 61.04%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,615.51% 232.52% 203.68% 146.69% 41.19%
Operating Expenses to Revenue		 4,746.05% 0.00% 0.00% 0.00% 0.00% 0.00% 4,192.20% 561.73% 406.94% 375.52% 102.23%
Earnings before Interest and Taxes (EBIT)		 -0.04 -0.03 -0.03 -3.31 -5.94 -4.10 -9.95 -10.00 -12 -12 -3.27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.04 -0.03 -0.03 -2.05 -5.68 -4.05 -9.86 -9.89 -12 -12 -2.82
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 5.06 6.45 2.86 2.58 32.23 5.04
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 5.47 6.58 2.89 2.62 35.10 5.08
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 173.91 12.94 4.74 7.67 2.95
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.06 0.00 57.97
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 145.50 7.69 3.19 7.25 2.41
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 -0.19 -0.48 0.00 0.49 0.00 0.00 0.01 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00
Financial Leverage		 -0.44 -0.17 1.30 -0.36 0.21 -3.97 -1.15 -1.12 -1.04 -0.95 -1.02
Leverage Ratio		 -0.01 -0.02 -2.18 -0.19 -0.13 6.39 1.47 1.28 1.32 1.90 2.05
Compound Leverage Factor		 -0.01 -0.02 -2.18 -0.27 -0.15 3.15 1.47 1.28 1.32 1.94 2.26
Debt to Total Capital		 0.00% 0.00% -23.12% -92.58% 0.00% 32.77% 0.00% 0.00% 0.88% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% -23.12% -92.58% 0.00% 32.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.88% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 123.12% 192.58% 200.00% 67.23% 100.00% 100.00% 99.12% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -1.53 -1.18 0.00 -0.25 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 14.48 -1.17 0.00 0.75 0.00 0.00 0.45 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -2.19 -1.13 0.00 -0.29 0.00 0.00 -0.01 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 20.69 -1.11 0.00 0.88 0.00 0.00 0.63 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 -77.93 -9.14 7.93 -1.99 -9.19 -22.30 -3.44
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.01 0.00 0.85 0.01 0.34 1.76 6.17 3.93 4.08 2.09 4.44
Quick Ratio		 0.01 0.00 0.77 0.01 0.29 1.71 5.88 3.61 2.97 0.74 3.40
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.01 0.00 0.65 -0.25 0.00 -3.97 -7.77 -5.83 -11 -6.70 -4.10
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -18,494.51% -2,797.83% -12,824.92% -2,732.13% -3,421.75% -9,161.49% -3,471.01%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -0.18 0.00 -0.53 -2,544.49 0.00 0.00 -29.26 -12.27
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -1.51 -12.88 -0.46 -2,817.83 0.00 0.00 -48.09 -8.49
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -1.51 -13.02 -0.47 -2,839.80 0.00 0.00 -48.61 -8.74
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 2.12 0.00 0.00 0.00 0.00 0.00 0.04 0.20 0.33 0.51 1.50
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 51.98 0.00 0.00 16.79
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.60 1.23 1.09 1.63
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 1.25 7.35 7.75 7.33 35.79
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.43 0.33 1.86 2.77 3.88
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.02 0.00 0.00 21.74
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 605.53 296.60 335.41 224.28
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 854.22 1,098.55 196.75 131.82 94.08
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -854.22 -486.00 99.85 203.58 151.94
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.04 -0.06 -0.74 -2.64 -1.50 -0.96 -0.35 -1.54 0.98 -0.64 0.50
Invested Capital Turnover		 -0.04 0.00 0.00 0.00 0.00 0.00 -0.37 -2.25 -12.28 20.07 -178.05
Increase / (Decrease) in Invested Capital		 -0.03 -0.03 -0.68 -1.90 0.00 0.54 0.62 -1.19 2.52 -1.62 1.14
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 22 7.42 35 16 11 25 29
Market Capitalization		 0.00 0.00 0.00 0.00 22 10 42 27 16 26 36
Book Value per Share		 ($0.01) ($0.02) ($0.05) ($0.64) ($0.09) $0.09 $0.55 $0.59 $0.26 $0.03 $0.18
Tangible Book Value per Share		 ($0.01) ($0.02) ($0.09) ($0.67) ($0.11) $0.09 $0.53 $0.59 $0.26 $0.03 $0.18
Total Capital		 -0.04 -0.08 -0.22 -2.62 -1.24 3.07 6.55 9.60 6.30 0.82 7.07
Total Debt		 0.00 0.00 0.05 2.42 0.00 1.01 0.00 0.00 0.06 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00
Net Debt		 -0.00 0.00 -0.47 2.39 -0.26 -3.03 -6.90 -11 -5.27 -1.46 -6.57
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.06 0.12 0.07 0.28 0.38 0.12 0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.04 -0.08 -0.57 -1.48 -1.73 -1.23 -0.79 -2.06 0.20 0.96 1.35
Debt-free Net Working Capital (DFNWC)		 -0.04 -0.08 -0.05 -1.45 -1.47 2.81 6.11 9.08 5.52 2.42 7.92
Net Working Capital (NWC)		 -0.04 -0.08 -0.10 -3.87 -1.47 1.80 6.11 9.08 5.52 2.42 7.92
Net Nonoperating Expense (NNE)		 0.01 0.04 0.02 2.91 2.71 10 2.80 2.98 3.49 4.00 0.65
Net Nonoperating Obligations (NNO)		 -0.00 0.02 -0.47 2.39 -0.26 -3.03 -6.90 -11 -5.27 -1.46 -6.57
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 1.26 0.26 0.05 0.08 0.11 0.15 0.35 0.45
Debt-free, Cash-free Net Working Capital to Revenue		 -4,604.66% 0.00% 0.00% 0.00% 0.00% 0.00% -325.58% -97.37% 5.80% 27.73% 11.18%
Debt-free Net Working Capital to Revenue		 -4,578.14% 0.00% 0.00% 0.00% 0.00% 0.00% 2,514.97% 428.16% 162.00% 70.02% 65.49%
Net Working Capital to Revenue		 -4,578.14% 0.00% 0.00% 0.00% 0.00% 0.00% 2,514.97% 428.16% 162.00% 70.02% 65.49%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) ($0.01) ($0.01) ($0.77) ($0.57) ($0.84) ($0.93) ($0.63) ($0.65) ($0.46) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 5.07M 5.07M 5.07M 7.86M 13.70M 22.99M 16.19M 16.00M 18.12M 26.76M 40.15M
Adjusted Diluted Earnings per Share		 ($0.01) ($0.01) ($0.01) ($0.77) ($0.57) ($0.84) ($0.93) $0.00 $0.00 ($0.46) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 5.07M 5.07M 5.07M 7.86M 13.70M 22.99M 16.19M 16.24M 23.96M 26.76M 40.15M
Adjusted Basic & Diluted Earnings per Share		 ($0.01) ($0.01) ($0.01) ($0.77) ($0.57) ($0.84) ($0.93) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.07M 5.07M 5.07M 6.61M 11.86M 16.25M 10.70M 16.24M 23.96M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -0.03 -0.02 -0.02 -2.15 -4.07 -3.43 -7.15 -7.02 -8.37 -8.32 -2.96
Normalized NOPAT Margin		 -3,252.24% 0.00% 0.00% 0.00% 0.00% 0.00% -2,944.03% -331.20% -245.59% -240.98% -24.46%
Pre Tax Income Margin		 -4,688.75% 0.00% 0.00% 0.00% 0.00% 0.00% -4,094.60% -471.67% -348.03% -356.74% -29.80%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -2.37 -7.09 -0.54 -3,257.49 0.00 0.00 -52.79 -9.79
NOPAT to Interest Expense		 0.00 0.00 0.00 -1.54 -9.71 -0.46 -2,342.86 0.00 0.00 -36.34 -8.86
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -2.37 -14.32 -0.56 -3,279.46 0.00 0.00 -53.32 -10.04
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -1.54 -9.85 -0.47 -2,364.83 0.00 0.00 -36.86 -9.10
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for NeuroOne Medical Technologies

This table displays calculated financial ratios and metrics derived from NeuroOne Medical Technologies' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 23,919,184.00 25,930,926.00 25,930,926.00 25,930,926.00 25,930,926.00 25,930,926.00 25,930,926.00 25,930,926.00 - 25,930,926.00 25,930,926.00
DEI Adjusted Shares Outstanding		 23,919,184.00 25,930,926.00 25,930,926.00 25,930,926.00 25,930,926.00 720,304.00 25,930,926.00 25,930,926.00 - 720,304.00 720,304.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.14 -0.11 -0.11 -0.13 0.07 -3.15 -0.06 -0.06 - -3.31 -2.79
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 753.25% 195.45% 31.10% -87.61% 541.76% 0.67% 105.39% 906.64% -53.90% 34.29% 16.34%
EBITDA Growth		 -91.32% 20.15% 20.84% 3.79% 172.05% 21.09% 47.31% 58.39% -157.96% -5.31% -37.50%
EBIT Growth		 -93.04% 18.95% 20.22% 0.43% 163.08% 20.47% 46.11% 58.53% -168.14% -4.91% -34.51%
NOPAT Growth		 -90.01% 17.44% 20.41% 11.00% 172.10% 7.14% 32.47% 51.32% -169.84% 10.55% -28.50%
Net Income Growth		 -93.04% 18.95% 20.22% -6.87% 153.37% 20.47% 45.77% 51.67% -180.54% -4.91% -33.68%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 142.86% 20.47% 70.00% 54.55% -150.00% -4.91% -47.37%
Operating Cash Flow Growth		 -9.08% 38.75% 19.72% 8.13% 105.46% 97.42% 38.00% 42.79% -1,597.64% -2,266.61% 26.08%
Free Cash Flow Firm Growth		 -134.87% 25.94% 4.74% 92.58% 146.00% 89.55% 98.82% -497.43% -235.63% -1,518.63% -9,805.75%
Invested Capital Growth		 228.29% 51.81% 91.17% -164.96% 3.67% -113.69% -80.45% 178.70% 57.71% 1,316.93% 472.72%
Revenue Q/Q Growth		 -55.50% 40.88% -40.04% -67.03% 2,204.27% -77.90% 22.32% 61.61% 5.54% -35.63% 5.96%
EBITDA Q/Q Growth		 -6.95% 14.97% 3.21% -9.31% 180.10% -193.12% 35.38% 13.67% -11.56% -69.20% 15.62%
EBIT Q/Q Growth		 -6.69% 14.64% 3.07% -12.79% 167.60% -207.61% 34.31% 13.21% -11.08% -65.66% 15.77%
NOPAT Q/Q Growth		 -7.13% 14.88% 3.19% -0.82% 186.79% -209.63% 29.60% 27.33% -24.52% -40.41% -1.13%
Net Income Q/Q Growth		 -6.69% 14.64% 3.07% -21.07% 153.28% -227.18% 33.90% -7.89% 11.20% -65.66% 15.77%
EPS Q/Q Growth		 0.00% 21.43% 9.09% -10.00% 154.55% -227.18% 57.14% -66.67% 40.00% -65.66% 0.00%
Operating Cash Flow Q/Q Growth		 -31.23% 42.90% -8.52% -12.98% 107.80% -126.99% -2,506.70% -4.25% -104.23% 57.36% 18.58%
Free Cash Flow Firm Q/Q Growth		 24.36% 30.06% -8.57% 87.08% 568.70% -115.89% 87.75% -6,447.09% -6.41% -89.67% 25.03%
Invested Capital Q/Q Growth		 76.87% -18.27% 12.81% -139.84% 382.27% -110.79% 261.07% 60.37% 465.64% -16.71% -24.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 27.24% 28.35% 34.13% 51.81% 30.71% 55.61% 53.94% 55.77% 54.20% 53.18% 59.94%
EBITDA Margin		 -336.14% -202.88% -327.50% -1,085.69% 37.74% -159.03% -84.02% -44.88% -47.44% -124.70% -99.30%
Operating Margin		 -346.80% -209.55% -338.34% -1,034.48% 27.27% -193.29% -111.23% -50.02% -59.02% -128.74% -122.87%
EBIT Margin		 -342.14% -207.30% -335.14% -1,146.45% 33.63% -163.76% -87.94% -47.23% -49.71% -127.92% -101.68%
Profit (Net Income) Margin		 -342.14% -207.30% -335.14% -1,230.55% 28.46% -163.76% -88.49% -59.08% -49.71% -127.92% -101.68%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 107.34% 84.61% 100.00% 100.63% 125.09% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -914.92% -645.51% -1,044.17% -14,530.51% 134.89% -1,934.18% -783.13% 0.00% -155.18% -763.00% -773.25%
ROIC Less NNEP Spread (ROIC-NNEP)		 -896.10% -621.76% -1,008.04% -14,489.52% 131.01% -1,913.16% -779.25% 0.00% -144.84% -728.08% -766.96%
Return on Net Nonoperating Assets (RNNOA)		 734.79% 465.78% 653.34% 13,784.31% -67.97% 1,442.43% 645.90% 0.00% 72.84% 473.24% 631.72%
Return on Equity (ROE)		 -180.13% -179.73% -390.83% -746.20% 66.92% -491.75% -137.24% -91.34% -82.34% -289.77% -141.53%
Cash Return on Invested Capital (CROIC)		 -944.35% -811.09% -764.79% 0.00% -272.10% 0.00% -280.13% -816.25% -275.39% -326.07% -665.60%
Operating Return on Assets (OROA)		 -188.75% -170.50% -337.80% -587.90% 47.78% -291.19% -107.65% -70.73% -57.49% -195.56% -113.24%
Return on Assets (ROA)		 -188.75% -170.50% -337.80% -631.03% 40.43% -291.19% -108.33% -88.47% -57.49% -195.56% -113.24%
Return on Common Equity (ROCE)		 -180.13% -179.73% -390.83% -746.20% 66.92% -491.75% -137.24% -91.34% -82.34% -289.77% -141.53%
Return on Equity Simple (ROE_SIMPLE)		 -304.92% -332.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.37 -2.02 -1.96 -1.97 1.71 -1.88 -1.32 -0.96 -1.20 -1.68 -1.70
NOPAT Margin		 -242.76% -146.68% -236.84% -724.14% 27.27% -135.30% -77.86% -35.02% -41.32% -90.12% -86.01%
Net Nonoperating Expense Percent (NNEP)		 -18.82% -23.74% -36.13% -40.99% 3.89% -21.02% -3.89% -16.42% -10.34% -34.92% -6.29%
Return On Investment Capital (ROIC_SIMPLE)		 -53.72% -52.41% -60.71% -239.86% 58.30% -166.63% -15.81% -13.57% -18.67% -32.46% -44.18%
Cost of Revenue to Revenue		 72.76% 71.65% 65.87% 48.19% 21.47% 44.39% 46.06% 44.23% 45.80% 46.82% 40.06%
SG&A Expenses to Revenue		 222.32% 145.43% 227.80% 677.30% 32.57% 139.95% 95.45% 65.00% 65.18% 103.08% 110.58%
R&D to Revenue		 151.72% 92.47% 144.67% 408.99% 18.68% 108.95% 69.72% 40.79% 48.04% 78.84% 72.23%
Operating Expenses to Revenue		 374.04% 237.90% 372.47% 1,086.29% 51.25% 248.90% 165.17% 105.79% 113.22% 181.92% 182.80%
Earnings before Interest and Taxes (EBIT)		 -3.34 -2.86 -2.77 -3.12 2.11 -2.27 -1.49 -1.29 -1.44 -2.38 -2.01
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.29 -2.79 -2.70 -2.96 2.37 -2.20 -1.42 -1.23 -1.37 -2.32 -1.96
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.58 8.07 7.27 32.23 8.69 140.96 4.03 5.04 5.96 46.72 7.05
Price to Tangible Book Value (P/TBV)		 8.75 8.23 7.45 35.10 8.88 148.35 4.06 5.08 6.00 47.03 7.11
Price to Revenue (P/Rev)		 8.88 6.00 4.07 7.67 2.91 18.12 3.42 2.95 4.38 25.80 2.81
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 20.28 20.18 12.78 0.00 13.53 0.00 80.18 57.97 12.18 99.12 13.71
Enterprise Value to Revenue (EV/Rev)		 8.25 5.53 3.81 7.25 2.79 17.97 2.61 2.41 3.97 25.51 2.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.07 0.00 0.00 0.00 0.02 0.00 0.00 0.02 0.02
Long-Term Debt to Equity		 0.00 0.00 0.07 0.00 0.00 0.00 0.02 0.00 0.00 0.02 0.02
Financial Leverage		 -0.82 -0.75 -0.65 -0.95 -0.52 -0.75 -0.83 -1.02 -0.50 -0.65 -0.82
Leverage Ratio		 1.23 1.34 1.54 1.90 1.68 1.98 1.41 2.05 1.61 1.94 1.42
Compound Leverage Factor		 1.23 1.34 1.54 2.04 1.42 1.98 1.41 2.56 1.61 1.94 1.42
Debt to Total Capital		 0.00% 0.00% 6.52% 0.00% 0.00% 0.00% 2.10% 0.00% 0.00% 1.79% 1.91%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 6.52% 0.00% 0.00% 0.00% 2.10% 0.00% 0.00% 1.79% 1.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 93.48% 100.00% 100.00% 100.00% 97.90% 100.00% 100.00% 98.21% 98.09%
Debt to EBITDA		 0.00 0.00 -0.02 0.00 0.00 0.00 -0.04 0.00 0.00 -0.01 -0.01
Net Debt to EBITDA		 0.00 0.00 0.12 0.00 0.00 0.00 1.73 0.00 0.00 0.41 0.27
Long-Term Debt to EBITDA		 0.00 0.00 -0.02 0.00 0.00 0.00 -0.04 0.00 0.00 -0.01 -0.01
Debt to NOPAT		 0.00 0.00 -0.02 0.00 0.00 0.00 -0.04 0.00 0.00 -0.02 -0.01
Net Debt to NOPAT		 0.00 0.00 0.16 0.00 0.00 0.00 1.98 0.00 0.00 0.53 0.36
Long-Term Debt to NOPAT		 0.00 0.00 -0.02 0.00 0.00 0.00 -0.04 0.00 0.00 -0.02 -0.01
Altman Z-Score		 -0.08 -5.85 -13.69 -16.79 -8.30 5.69 -1.07 -2.83 -1.13 42.91 -11.33
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.68 3.06 2.42 2.09 3.64 2.13 7.13 4.44 6.41 4.21 2.84
Quick Ratio		 2.33 1.94 1.20 0.74 2.23 0.93 5.64 3.40 4.95 2.78 1.54
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.58 -2.50 -2.72 -0.35 1.65 -0.26 -0.03 -2.10 -2.23 -4.24 -3.18
Operating Cash Flow to CapEx		 -10,259.33% 0.00% 0.00% -7,226.35% 852.10% -1,770.55% 0.00% -14,383.63% -7,645.47% -3,449.76% -5,502.77%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -1.54 5.07 0.00 -3.44 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -11.65 0.64 0.00 -156.94 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -11.81 0.57 0.00 -156.94 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.55 0.82 1.01 0.51 1.42 1.78 1.22 1.50 1.16 1.53 1.11
Accounts Receivable Turnover		 13.37 13.47 0.00 0.00 6.01 20.03 0.00 16.79 3.47 8.30 0.00
Inventory Turnover		 1.66 2.12 1.69 1.09 1.70 1.68 1.56 1.63 2.19 2.13 2.01
Fixed Asset Turnover		 10.17 10.17 10.15 7.33 19.73 21.08 24.47 35.79 27.82 32.51 36.64
Accounts Payable Turnover		 2.57 3.04 3.25 2.77 4.00 3.12 4.69 3.88 6.07 4.54 6.12
Days Sales Outstanding (DSO)		 27.29 27.10 0.00 0.00 60.75 18.22 0.00 21.74 105.34 44.00 0.00
Days Inventory Outstanding (DIO)		 220.38 172.34 216.49 335.41 214.66 217.67 234.29 224.28 166.87 171.35 182.00
Days Payable Outstanding (DPO)		 142.26 120.23 112.37 131.82 91.24 117.03 77.88 94.08 60.16 80.36 59.69
Cash Conversion Cycle (CCC)		 105.42 79.21 104.12 203.58 184.16 118.86 156.41 151.94 212.05 134.99 122.31
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.74 1.42 1.60 -0.64 1.80 -0.19 0.31 0.50 2.84 2.37 1.79
Invested Capital Turnover		 3.77 4.40 4.41 20.07 4.95 14.30 10.06 -178.05 3.76 8.47 8.99
Increase / (Decrease) in Invested Capital		 1.21 0.48 0.76 -1.62 0.06 -1.61 -1.29 1.14 1.04 2.56 1.48
Enterprise Value (EV)		 35 29 20 25 24 157 25 29 35 234 25
Market Capitalization		 38 31 22 26 26 159 33 36 38 237 27
Book Value per Share		 $0.18 $0.15 $0.11 $0.03 $0.10 $0.22 $0.17 $0.18 $0.13 $0.60 $0.44
Tangible Book Value per Share		 $0.18 $0.15 $0.11 $0.03 $0.09 $0.21 $0.17 $0.18 $0.13 $0.59 $0.43
Total Capital		 4.42 3.85 3.22 0.82 2.94 1.13 8.35 7.07 6.40 5.17 3.84
Total Debt		 0.00 0.00 0.21 0.00 0.00 0.00 0.18 0.00 0.00 0.09 0.07
Total Long-Term Debt		 0.00 0.00 0.21 0.00 0.00 0.00 0.18 0.00 0.00 0.09 0.07
Net Debt		 -2.68 -2.43 -1.41 -1.46 -1.13 -1.32 -7.86 -6.57 -3.56 -2.71 -1.97
Capital Expenditures (CapEx)		 0.04 0.00 0.00 0.04 0.02 0.00 0.00 0.01 0.04 0.04 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.03 0.73 0.77 0.96 3.01 0.67 0.71 1.35 3.25 2.61 1.70
Debt-free Net Working Capital (DFNWC)		 3.71 3.17 2.39 2.42 4.14 1.99 8.74 7.92 6.81 5.42 3.75
Net Working Capital (NWC)		 3.71 3.17 2.39 2.42 4.14 1.99 8.74 7.92 6.81 5.42 3.75
Net Nonoperating Expense (NNE)		 0.97 0.83 0.81 1.38 -0.07 0.39 0.18 0.66 0.24 0.70 0.31
Net Nonoperating Obligations (NNO)		 -2.68 -2.43 -1.41 -1.46 -1.13 -1.32 -7.86 -6.57 -3.56 -2.71 -1.97
Total Depreciation and Amortization (D&A)		 0.06 0.06 0.06 0.17 0.26 0.07 0.07 0.06 0.07 0.06 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 24.09% 14.18% 14.40% 27.73% 34.36% 7.66% 7.32% 11.18% 37.25% 28.44% 17.95%
Debt-free Net Working Capital to Revenue		 86.87% 61.16% 44.53% 70.02% 47.33% 22.73% 90.82% 65.49% 78.12% 58.94% 39.58%
Net Working Capital to Revenue		 86.87% 61.16% 44.53% 70.02% 47.33% 22.73% 90.82% 65.49% 78.12% 58.94% 39.58%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.14) ($0.11) ($0.10) ($0.11) $0.06 ($2.52) ($0.03) ($0.05) ($0.03) ($0.28) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding		 24.00M 25.91M 27.35M 26.76M 30.84M 864.22K 48.60M 40.15M 50.33M 8.48M 8.66M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.11) $0.06 ($2.52) ($0.03) ($0.05) ($0.03) ($0.28) ($0.28)
Adjusted Weighted Average Diluted Shares Outstanding		 25.93M 27.52M 30.81M 26.76M 30.88M 864.22K 48.60M 40.15M 50.33M 8.48M 8.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.93M 27.52M 30.81M 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.37 -2.02 -1.96 -1.97 1.20 -1.88 -1.32 -0.96 -1.20 -1.68 -1.70
Normalized NOPAT Margin		 -242.76% -146.68% -236.84% -724.14% 19.09% -135.30% -77.86% -35.02% -41.32% -90.12% -86.01%
Pre Tax Income Margin		 -342.14% -207.30% -335.14% -1,230.55% 28.46% -163.76% -88.49% -59.08% -49.71% -127.92% -101.68%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -13.63 6.50 0.00 -159.95 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -8.61 5.27 0.00 -141.62 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -13.79 6.42 0.00 -159.95 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -8.77 5.19 0.00 -141.62 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

NeuroOne Medical Technologies showed meaningful top-line growth in Q2 2026, but the company remains deeply unprofitable and continues to burn cash. Revenue rose year over year and the balance sheet still shows more cash than debt, yet operating losses and dilution remain major issues for investors to watch.

  • Revenue grew year over year in Q2 2026. Operating revenue increased to $1.86 million from $1.70 million in Q3 2025 and $1.39 million in Q2 2025, showing continued commercialization progress.
  • Gross profit improved versus the prior quarter. Q2 2026 gross profit was $990,264, up from $914,835 in Q3 2025 and above the Q2 2025 level of $771,061.
  • The company still has a cash cushion. Cash and equivalents were $2.8 million at the end of Q2 2026, with total current assets of $7.1 million versus $1.69 million in current liabilities.
  • Leverage appears manageable for now. Total liabilities of $2.49 million were below total equity of $5.08 million, so the balance sheet is not highly stretched.
  • Other income helped offset losses in Q2 2026. The company posted $15,175 of net other income, which slightly reduced the pretax loss.
  • Capital spending remains modest. Purchases of property and equipment were only $38,516 in Q2 2026, suggesting limited near-term capex pressure.
  • Operating losses widened in Q2 2026 versus the prior quarter. Operating loss was $2.40 million, compared with a $1.71 million loss in Q1 2026 and a $1.37 million loss in Q4 2025.
  • Cash burn remains significant. Operating cash flow was negative $1.33 million in Q2 2026 after negative $3.12 million in Q1 2026, meaning the business is still consuming cash to fund operations.
  • Shares outstanding continue to rise sharply. Weighted average basic shares were 8.48 million in Q2 2026, up from 5.03 million in Q1 2026 and far above 2025 levels, signaling dilution.
  • Retained earnings remain deeply negative. The company’s accumulated losses were still large at negative $82.4 million, reflecting years of operating losses.

Bottom line: NMTC is showing real revenue growth, which is encouraging for an early-stage medtech company, but profitability and cash generation are still far away. The stock likely remains highly speculative, with future performance dependent on continued sales growth, tighter expense control, and avoiding excessive dilution.

08/30/26 09:46 AM ETAI Generated. May Contain Errors.

NeuroOne Medical Technologies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NeuroOne Medical Technologies' fiscal year ends in September. Their fiscal year 2025 ended on September 30, 2025.

NeuroOne Medical Technologies' net income appears to be on an upward trend, with a most recent value of -$3.61 million in 2025, rising from -$36.24 thousand in 2014. The previous period was -$12.32 million in 2024. Check out NeuroOne Medical Technologies' forecast to explore projected trends and price targets.

NeuroOne Medical Technologies' total operating income in 2025 was -$4.23 million, based on the following breakdown:
  • Total Gross Profit: $5.14 million
  • Total Operating Expenses: $12.37 million

Over the last 10 years, NeuroOne Medical Technologies' total revenue changed from $773.00 in 2014 to $12.10 million in 2025, a change of 1,564,931.3%.

NeuroOne Medical Technologies' total liabilities were at $3.71 million at the end of 2025, a 18.4% decrease from 2024, and a 4,355.9% increase since 2015.

In the past 10 years, NeuroOne Medical Technologies' cash and equivalents has ranged from $0.00 in 2015 to $8.16 million in 2022, and is currently $6.57 million as of their latest financial filing in 2025.

Over the last 10 years, NeuroOne Medical Technologies' book value per share changed from -0.01 in 2014 to 0.18 in 2025, a change of -2,615.7%.


Related Companies

Financial statements for NASDAQ:NMTC last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
A Worldwide Gold Lockdown Is Now Underway
Gold has spiked above $4,400 an ounce as central bankers stockpile at one of the fastest paces in decades, acc...
Stansberry Research | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Bank of America grew this stake 139%
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel